Variant report
Variant | nsv514415 |
---|---|
Chromosome Location | chr7:48391758-48401622 |
allele | n/a |
Outlinks | Ensembl   UCSC |
- TF binding region (count:0)
- CpG islands (count:0)
- Chromatin interactive region (count:0)
- LncRNA region (count:0)
- Mature miRNA region (count: 0)
- miRNA target sites (count:0)
No data |
No data |
No data |
No data |
No data |
No data |
No data |
No. | Variant name | Chromosome position | Chromatin state | Related regulatory elements | Target genes | Extended variants | Associated traits |
---|---|---|---|---|---|---|---|
1 | rs570157293 | chr7:48391764-48391765 | Weak transcription Enhancers Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
2 | rs369958763 | chr7:48391768-48391769 | Weak transcription Enhancers Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
3 | rs201772699 | chr7:48391821-48391822 | Weak transcription Enhancers Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
4 | rs373024545 | chr7:48391835-48391836 | Weak transcription Enhancers Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
5 | rs199919712 | chr7:48391844-48391845 | Weak transcription Enhancers Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
6 | rs376643039 | chr7:48391861-48391862 | Weak transcription Enhancers Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
7 | rs369135279 | chr7:48391862-48391863 | Weak transcription Enhancers Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
8 | rs372937831 | chr7:48391880-48391881 | Weak transcription Enhancers Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
9 | rs200761560 | chr7:48391885-48391886 | Weak transcription Enhancers Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
10 | rs566783688 | chr7:48391886-48391887 | Weak transcription Enhancers Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
11 | rs377328710 | chr7:48391911-48391912 | Weak transcription Enhancers Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
12 | rs370917914 | chr7:48391923-48391924 | Weak transcription Enhancers Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
13 | rs373657967 | chr7:48391929-48391930 | Weak transcription Enhancers Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
14 | rs376331882 | chr7:48391935-48391936 | Weak transcription Enhancers Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
15 | rs371083548 | chr7:48391973-48391974 | Weak transcription Enhancers Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
16 | rs150067467 | chr7:48391983-48391984 | Weak transcription Enhancers Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
17 | rs367810264 | chr7:48391988-48391989 | Weak transcription Enhancers Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
18 | rs530254670 | chr7:48392001-48392002 | Weak transcription Enhancers Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
19 | rs370669847 | chr7:48392011-48392012 | Weak transcription Enhancers Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
20 | rs569366797 | chr7:48392027-48392028 | Weak transcription Enhancers Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
21 | rs374129283 | chr7:48392054-48392055 | Weak transcription Enhancers Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
22 | rs538389782 | chr7:48392065-48392066 | Weak transcription Enhancers Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
23 | rs368428844 | chr7:48392079-48392080 | Weak transcription Enhancers Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
24 | rs558287023 | chr7:48392093-48392094 | Weak transcription Enhancers Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
25 | rs77901701 | chr7:48392110-48392111 | Weak transcription Enhancers Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
26 | rs376497539 | chr7:48392124-48392125 | Weak transcription Enhancers Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
27 | rs540638016 | chr7:48392140-48392141 | Weak transcription Enhancers Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
28 | rs554142502 | chr7:48392160-48392161 | Weak transcription Enhancers Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
29 | rs551002195 | chr7:48392200-48392201 | Weak transcription Enhancers Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
30 | rs542836760 | chr7:48392207-48392208 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
31 | rs562781571 | chr7:48392220-48392221 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
32 | rs140903744 | chr7:48392221-48392222 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
33 | rs543856046 | chr7:48392226-48392227 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
34 | rs181190767 | chr7:48392229-48392230 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
35 | rs371572681 | chr7:48392247-48392248 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
36 | rs371855262 | chr7:48392289-48392290 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
37 | rs568898156 | chr7:48392308-48392309 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
38 | rs144852128 | chr7:48392319-48392320 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
39 | rs373184325 | chr7:48392321-48392322 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
40 | rs536835468 | chr7:48392345-48392346 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
41 | rs548902597 | chr7:48392370-48392371 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
42 | rs569026743 | chr7:48392376-48392377 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
43 | rs538047415 | chr7:48392427-48392428 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
44 | rs545576477 | chr7:48392441-48392442 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
45 | rs558250021 | chr7:48392484-48392485 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
46 | rs571790202 | chr7:48392499-48392500 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
47 | rs11772384 | chr7:48392514-48392515 | Weak transcription Enhancers | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | mRNA abundance |
48 | rs576923940 | chr7:48392517-48392518 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
49 | rs17132258 | chr7:48392524-48392525 | Weak transcription Enhancers | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
50 | rs186512857 | chr7:48392541-48392542 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
Disease | PMID | Source |
---|---|---|
Glioblastoma multiforme | 17387387 | CNVD |
Astrocytoma | 17387387 | CNVD |
Esophageal squamous carcinoma | 21637470 | CNVD |
Biliary cancer | 19435499 | CNVD |
Wilms tumour | 21544195 | CNVD |
Neuroblastoma | 18923191 | CNVD |
Glioma | 21971842 | CNVD |
Glioblastoma multiforme | 21080181 | CNVD |
Liposarcoma | 21253554 | CNVD |
Medulloblastoma | 21979893 | CNVD |
Oligodendroglial tumors | 17285580 | CNVD |
Oral cancer | 21386901 | CNVD |
colon cancer | 17210682 | CNVD |
Lung adenocarcinoma | 21810691 | CNVD |
Endometrial cancer | 22040021 | CNVD |
Breast cancer | 21264507 | CNVD |
Colorectal cancer | 19359472 | CNVD |
Hypothalamic hamartomas | 18252217 | CNVD |
Human rectal carcinomas | 16397240 | CNVD |
Peripheral t-cell lymphoma | 19118030 | CNVD |
Medulloblastoma | 18056178 | CNVD |
Basal cell lymphoma | 17170743 | CNVD |
Ewing''s sarcoma | 21437220 | CNVD |
Thyroid cancer | 19087340 | CNVD |
Seminomas | 18059402 | CNVD |
Testicular cancer | 18059402 | CNVD |
Chronic lymphocytic leukemia | 21546498 | CNVD |
Autism | 19415332 | CNVD |
Pleomorphic xanthoastrocytoma | 20730472 | CNVD |
T-cell lymphomas | 19863542 | CNVD |
Malaria | 21533027 | CNVD |
Melanoma | 18172304 | CNVD |
Renal cell carcinoma | 19461508 | CNVD |
head and neck squamous cell carcinoma | 19289630 | CNVD |
Stenocardia | 21860640 | CNVD |
Vasospasm | 21860640 | CNVD |
Acute lymphoblastic leukemia | 20435627 | CNVD |
Ewing''s sarcoma | 17952124 | CNVD |
Lung cancer | 18438408 | CNVD |
lymphocytic leukemia | 21291569 | CNVD |
Endometrioid adenocarcinoma | 16974079 | CNVD |
Cancer | 21637783 | CNVD |
Squamous cell cancer | 20885788 | CNVD |
Breast cancer | 16397240 | CNVD |
Non-small cell lung cancer | 21829676 | CNVD |
Glioblastoma multiforme | 17002787 | CNVD |
Autism | 22495311 | CNVD |
Glioblastoma multiforme | 18628472 | CNVD |
Cancer | 21183584 | CNVD |
Breast cancer | 21785460 | CNVD |
Follicular lymphoma | 20505157 | CNVD |
Williams-beuren syndrome | 22470819 | CNVD |
T-cell prolymphocytic leukemia | 19278963 | CNVD |
Breast cancer | 21364760 | CNVD |
Acute myeloid leukemia | 21251322 | CNVD |
Acute lymphoblastic leukemia | 20067559 | CNVD |
Multiple myeloma | 16461302 | CNVD |
Glioblastoma multiforme | 21750150 | CNVD |
Hepatocellular carcinoma | 16750200 | CNVD |
Acute myeloid leukemia | 17237825 | CNVD |
Gastric cancer | 24379144 | CNVD |
T-cell prolymphocytic leukemia | 17713554 | CNVD |
Abnormal phenotypes | 18644119 | CNVD |
Gastrointestinal stromal cancer | 20877625 | CNVD |
Pancreatic endocrine tumor | 17639061 | CNVD |
Esophageal cancer | 21851588 | CNVD |
Lung adenocarcinoma | 17086460 | CNVD |
Lung cancer | 17086460 | CNVD |
Non-small cell lung cancer | 17643093 | CNVD |
Ovarian cancer | 18182111 | CNVD |
Colorectal cancer | 16272173 | CNVD |
Glioblastoma multiforme | 17369134 | CNVD |
Barrett''s esophagus | 18559552 | CNVD |
head and neck squamous cell carcinoma | 16943533 | CNVD |
Anaplastic thyroid cancer | 17079354 | CNVD |
Basal-like breast cancer | 17875215 | CNVD |
Colorectal cancer | 16882699 | CNVD |
Colorectal cancer | 18794099 | CNVD |
Gastrointestinal stromal cancer | 17643098 | CNVD |
Lung cancer | 18381415 | CNVD |
Metastatic colorectal cancer | 17664472 | CNVD |
Non-small cell lung cancer | 19255323 | CNVD |
Non-small cell lung cancer | 17673923 | CNVD |
Non-small cell lung cancer | 17975165 | CNVD |
Non-small cell lung cancer | 19622585 | CNVD |
Ovarian cancer | 16607561 | CNVD |
Squamous cell cancer | 19670535 | CNVD |
head and neck squamous cell carcinoma | 16818711 | CNVD |
small cell lung cancer | 18829487 | CNVD |
Breast cancer | 17661082 | CNVD |
Adenocarcinoma | 19260752 | CNVD |
Esophageal cancer | 16575012 | CNVD |
Lung adenocarcinoma | 19138956 | CNVD |
Lung adenocarcinoma | 18379350 | CNVD |
Lung adenocarcinoma | 18258923 | CNVD |
Lung cancer | 19138956 | CNVD |
Lung cancer | 18379350 | CNVD |
Lung cancer | 18258923 | CNVD |
Non-small cell lung cancer | 18304967 | CNVD |
Non-small cell lung cancer | 19451690 | CNVD |
Non-small cell lung cancer | 19260752 | CNVD |
Non-small cell lung cancer | 17079354 | CNVD |
Non-small cell lung cancer | 18559607 | CNVD |
Rectal cancer | 19506820 | CNVD |
Triple-negative breast cancer | 18950515 | CNVD |
head and neck squamous cell carcinoma | 18813952 | CNVD |
Non-small cell lung cancer | 17504988 | CNVD |
Non-small cell lung cancer | 16943533 | CNVD |
Non-small cell lung cancer | 18509184 | CNVD |
head and neck squamous cell carcinoma | 17538160 | CNVD |
Colorectal cancer | 19712476 | CNVD |
Lung adenocarcinoma | 19525976 | CNVD |
Lung cancer | 19525976 | CNVD |
Lung cancer | 19671679 | CNVD |
head and neck squamous cell carcinoma | 17671120 | CNVD |
small cell lung cancer | 20016488 | CNVD |
Myelofibrosis | 22110671 | CNVD |
Lissencephaly | 21572526 | CNVD |
Breast cancer | 17603634 | CNVD |
Acute myeloid leukemia | 16864856 | CNVD |
Pancreatic cancer | 17952125 | CNVD |
Colorectal cancer | 21645411 | CNVD |
Breast cancer | 22522925 | CNVD |
Autism | 22495309 | CNVD |
No. | Chromosome Location | Chromatin state | Cell line | Tissue |
---|---|---|---|---|
1 | chr7:48378800-48392800 | Weak transcription | iPS DF 19.11 Cell Line | embryonic stem cell |
2 | chr7:48384400-48392600 | Weak transcription | Primary hematopoietic stem cells | blood |
3 | chr7:48389400-48393000 | Enhancers | Primary monocytes fromperipheralblood | blood |
4 | chr7:48390200-48392200 | Flanking Active TSS | Monocytes-CD14+_RO01746 | blood |
5 | chr7:48390800-48392600 | Weak transcription | Primary hematopoietic stem cells G-CSF-mobilized Male | -- |
6 | chr7:48391600-48392000 | Flanking Active TSS | Primary neutrophils fromperipheralblood | blood |
7 | chr7:48392000-48392600 | Enhancers | Primary neutrophils fromperipheralblood | blood |
8 | chr7:48392200-48392800 | Enhancers | Monocytes-CD14+_RO01746 | blood |
9 | chr7:48392600-48392800 | Genic enhancers | Primary neutrophils fromperipheralblood | blood |
10 | chr7:48392600-48393400 | Strong transcription | Primary hematopoietic stem cells G-CSF-mobilized Male | -- |
11 | chr7:48392600-48395400 | Strong transcription | Primary hematopoietic stem cells | blood |
12 | chr7:48392800-48393000 | Enhancers | iPS DF 19.11 Cell Line | embryonic stem cell |
13 | chr7:48392800-48400600 | Strong transcription | Primary neutrophils fromperipheralblood | blood |
14 | chr7:48393000-48393800 | Weak transcription | Primary monocytes fromperipheralblood | blood |
15 | chr7:48393400-48395000 | Weak transcription | Primary hematopoietic stem cells G-CSF-mobilized Male | -- |
16 | chr7:48394600-48394800 | Enhancers | Primary monocytes fromperipheralblood | blood |
17 | chr7:48395400-48406400 | Weak transcription | Primary hematopoietic stem cells | blood |
18 | chr7:48398600-48399000 | Active TSS | H1 Derived Mesenchymal Stem Cells | ES cell derived |
19 | chr7:48399000-48399200 | Enhancers | H1 Derived Mesenchymal Stem Cells | ES cell derived |
20 | chr7:48400600-48403000 | Weak transcription | Primary neutrophils fromperipheralblood | blood |